Dr Hagop Kantarjian, MD has joined Actinium Pharmaceuticals, Inc. (API) clinical advisory board. Dr Kantarjian who heads the largest leukaemia service in the world at MD Anderson Cancer Centre in Houston, Texas will help the company in developing its clinical stage drug candidates in the field of hematologic oncology, Actimab-A and Iomab-B, as well as other earlier stage products.


"We are delighted to have Dr Kantarjian working with us and his vast expertise will be of significant benefit to the Company," said Jack Talley, CEO of Actinium Pharmaceuticals. "He is one of the foremost blood cancer experts in the world and has achieved many esteemed certifications, honors and awards over his career. Actinium has assembled a superb team of clinical experts to help guide our programs to their next milestones and ultimately expand the number of patients who are successfully in remission for acute myeloid leukemia or able to have a successful bone marrow transplant due to our product candidates."


API drug candidates Actimab-A and Iomab-B are currently in clinical trials in the US.


Actimab-A is being developed using Company's proprietary patented APIT technology and it consists of the monoclonal antibody Lintuzumab used to guide the alpha emitting radioisotope actinium 225 to malignant cells. The ongoing phase I/II trial is a prospective, open-label study, designed to determine the safety and efficacy of Actimab-A in newly diagnosed acute myeloid leukemia patients over the age of 60 who cannot tolerate current high dose chemotherapeutic regimens.


Iomab-B consists of the monoclonal antibody BC8 attached to the radioisotope iodine 131. It is currently in phase I and phase II clinical trials in a number of blood cancer indications as a preparatory regimen to allow bone marrow transplant. The Company is preparing for a pivotal trial in relapsed and refractory acute myeloid leukaemia patients over the age of 50.


Actinium Pharmaceuticals, Inc. is a biopharmaceutical company that develops innovative targeted payload immunotherapeutics based on its platform for the therapeutic utilization of radiopharmaceuticals in association with monoclonal antibodies.